New-TS3 study:

Analysis of the clinical and economic data, and positive social benefits of the Newcard* solution:

• 99% match with the SNDS base used by the French Health Insurance system
• first real study analysing the impact of remote monitoring over 4 years
• 8.9% mortality rate of patients monitored for 4 years using the Newcard solution

The full study will be presented at thecongress of the European Society of Cardiology to be held in Amsterdam the 27 August 2023 during the topic “Advancing remote monitoring” (9:15 to 10:00 am – Station 9)